Lawsuit against Humana moves forward over alleged securities fraud and misleading investors.

A court has allowed key claims in a securities fraud lawsuit against Humana and its former CEO and CFO to proceed. The lawsuit alleges Humana misled investors from July 2022 to October 2024 about rising costs as patients returned for care post-pandemic, inflating its stock price. Insiders sold over $104 million in stock during this time. When Humana revealed sharp declines in its plans' ratings in October 2024, the stock price dropped 22%. The law firm Schubert Jonckheer & Kolbe LLP is investigating potential wrongdoing by Humana's directors and officers, and current shareholders may have legal options.

Humana Inc. shares are trading at USD 403.17 on Pluang as of Oct 06, 2026 20:42 WIB, showing a mild 0.22% decline in the past day. The stock remains close to its 52-week high of USD 409.85, reflecting relative stability despite the ongoing securities fraud case. Investors typically hold Humana shares for about 53 days on Pluang, indicating moderate trading activity in this health sector stock.